A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

10,000

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

May 10, 2023

Study Completion Date

April 30, 2024

Conditions

COVID-19SARS-CoV-2 Infection

Interventions

BIOLOGICAL

SCTV01E

D0; intramuscular injection

BIOLOGICAL

Placebo

D0; intramuscular injection

Trial Locations (1)

Guizhou center for disease control and prevention, Guiyang

All Listed Sponsors

lead

Sinocelltech Ltd.

INDUSTRY